scholarly journals A Cross-Sectional Study on the Frequency of Behavioural and Psychological Symptoms of Dementia in Alzheimer’s Disease in a Tertiary Care Hospital of North Kerala

2021 ◽  
Vol 8 (24) ◽  
pp. 2006-2010
Author(s):  
Tess Ann Kurian ◽  
Sumesh Balachandran ◽  
Yesudas Kalathara Francis

BACKGROUND Behavioural and psychological symptoms of dementia (BPSD) are a heterogeneous group of clinical phenomena experienced during the course of dementia which are either subjectively reported by the patient or observed by the clinician. BPSD include agitation, aberrant motor behaviour, anxiety, elation, irritability, depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes. We wanted to determine the frequency of behavioural and psychological symptoms of dementia in patients with dementia of the Alzheimer’s type attending the Psychiatry Department in a tertiary care centre of north Kerala and to address the degree of caregiver distress. METHODS This is a hospital based cross sectional study. A consecutive sample of 72 patients of either gender of age group > 55 years who were diagnosed with Alzheimer’s dementia using DSM 4 - TR criteria attending Department of Psychiatry of GMC Kannur during the period March 2019 to February 2020 were included in the study. The primary caregivers were interviewed to obtain the sociodemographic profile of the patients and BEHAVE AD scale was administered to assess the BPSD in patients with Alzheimer’s dementia. Descriptive statistical tools like frequency and percentage were used. RESULTS The most common BPSD identified were diurnal rhythm disturbances or day-night disturbances observed in 79.2 % (N = 57) of the sample. This was followed by affective disturbances, paranoid and delusional ideations, anxieties, hallucinations and aggressiveness. The least reported was activity disturbances. CONCLUSIONS The frequency of BPSD is very high in dementia of Alzheimer’s type and the most frequent BPSD reported was diurnal rhythm disturbances. BPSD would impact negatively on the health of the individual and their respective caregivers. KEYWORDS Alzheimer’s Dementia, Behavioural and Psychological Symptoms of Dementia

Vacunas ◽  
2020 ◽  
Vol 21 (2) ◽  
pp. 95-104 ◽  
Author(s):  
Y.M. AlGoraini ◽  
N.N. AlDujayn ◽  
M.A. AlRasheed ◽  
Y.E. Bashawri ◽  
S.S. Alsubaie ◽  
...  

Author(s):  
Nandini Chatterjee ◽  
Supratick Chakraborty ◽  
Mainak Mukhopadhyay ◽  
Sinjon Ghosh ◽  
Bikramjit Barkandaj ◽  
...  

2020 ◽  
Vol 32 (1) ◽  
Author(s):  
Nearmeen M. Rashad ◽  
Marwa G. Amer ◽  
Waleed M. Reda Ashour ◽  
Hassan M. Hassanin

Abstract Background Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system with varied clinical features. Disease-modifying drugs (DMDs) of MS associated with different types of thyroiditis. In this cross-sectional study, we aimed to assess the prevalence of thyroid dysfunction in MS and to investigate the association between DMDs and the risk of thyroiditis in MS. A cross-sectional study included 100 patients with relapsing-remitting multiple sclerosis (RRMS) in relapse, and the diagnosed was according to revised McDonald’s criteria 2010. Results Our results revealed that the prevalence of thyroiditis was 40%; autoimmune (34%) and infective (6%) among patients with RRMS in relapse and cerebellar symptoms were significantly higher in patients with thyroiditis compared to patients without thyroiditis. Regarding the association between DMDs and thyroiditis, the prevalence of patients treated with interferon-beta-1b was higher in MS patients with thyroiditis compared to MS patients without thyroiditis. However, the prevalence of patients treated with interferon-beta-1a was lower in MS patients with thyroiditis compared to MS patients without thyroiditis. In addition, we found CMV infection was more common in patients treated by interferon beta-1b and candida infection was common in patients treated by fingolimod. Conclusions Thyroiditis is commonly observed in patients with RRMS in relapse and higher prevalence of patients treated with interferon-beta-1b which is commonly associated with thyroiditis and CMV infection; however, candida thyroid infection was common in MS patients treated by fingolimod.


Author(s):  
Sujeet A. Divhare ◽  
Satyashil Ingale

Background: Potential importance of drug –drug interactions (DDIs) is increasing as polypharmacy becomes more prevalent. Because additional data on the incidence and pattern of potential DDIs among diabetic patients are lacking in India, and supplemental pharmacodynamic or clinical outcome information is needed to address importance of a drug- drug interaction. Aim and objectives: To identify and analyze the pattern of DDIs in patients being prescribed anti-diabetic drugs in a tertiary care hospital. Material and Methods: This prospective cross-sectional study was carried out for a period of three months in 200 Type 2 diabetes mellitus (Type 2 DM) patients who were taking at least one antidiabetic agent during the period of past six months, of any age and either sex admitted in medicine ward of a tertiary care teaching hospital. Only one prescription was included for each patient on his/her 3rd day of hospitalization in the ward. Results: A total of 1217 drugs were prescribed in 200 prescriptions, resulting in an average of 6.1 drugs per prescription. A total of 637 potential DDIs were noted. The majority were seen in middle aged and elderly people. No overall difference was detected in the patients on insulin or metformin therapy taking or not taking additional drugs with the potential to interact. Worse control was found in the group of patients on sulphonylurea therapy taking interacting drugs (P <0.05). This difference was most marked in the group of patients over 60 years of age, who also had the highest intake of potentially interacting drugs (57%; <35 years-37%). Conclusion: Antidiabetic drugs have numerous interactions. A good practice is to use a drug­–drug interaction checker if any questions arise, several are available online. Quality care starts with the clinician obtaining a complete medication list for each patient at the start of each visit. Keywords: diabetes mellitus, drug interactions, hypoglycemic agents, drug therapy, co-morbidity, polypharmacy


Sign in / Sign up

Export Citation Format

Share Document